Improving detection of residual disease in pediatric acute myeloid leukemia
Official title: Preclinical Validation of Personalized Molecular Assays for Measurable Residual Disease Monitoring in Pediatric AML
Funded at University of Colorado Denver · NIH-10896412 · Data updated 2026-11-12
This study is looking for better ways to find leftover cancer cells in kids with acute myeloid leukemia, so doctors can spot those at risk of getting sick again and help them sooner for better treatment results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $227,905 |
| NIH project number | 5K08CA279762-02 |
| Project ID | NIH-10896412 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pediatric patients diagnosed with acute myeloid leukemia.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with AML may not benefit from this research.
What this research studies
This research focuses on developing advanced methods to detect residual disease in children with acute myeloid leukemia (AML). By utilizing innovative technologies such as digital PCR and next-generation sequencing, the study aims to identify patients at the highest risk of relapse early on. This early detection could lead to timely interventions, potentially improving treatment outcomes. The research is conducted by a team of experienced mentors in a supportive environment that enhances the chances of success.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and treatment strategies for children with AML, ultimately improving survival rates.
How similar studies have gone: Previous research has shown promise in using advanced molecular assays for disease monitoring, indicating a potential for success in this approach.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Winters, Amanda C — University of Colorado Denver
- Study coordinator: Winters, Amanda C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.